Table 3 Prognosis of KRAS mutant NSCLC received first-line treatment
Characteristics and treatment scheme | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
Median PFS (95%CI) (month) | P value | HR(95%CI) | P value | Median OS (95%CI)(month) | P value | HR(95%CI) | P value | |
Age (year) |  | 0.504 | – |  | 0.554 | – | ||
  < 65 | 8.1 (5.7–10.7) |  |  |  | 17.0 (11.8–22.1) |  |  |  |
  ≥ 65 | 9.8 (8.5–11.1) |  |  |  | 16.9 (13.0–20.9) |  |  |  |
Sex |  | 0.941 | 0.810(0.387–1.696) | 0.576 |  | 0.913 | 0.488(0.205–1.16) | 0.104 |
 Male | 9.0 (7.33–10.67) |  |  |  | 15.7 (13.2–18.2) |  |  |  |
 Female | 8.0 (4.39–11.61) |  |  |  | 15.9 (12.7–19.1) |  |  |  |
Smoking history |  | 0.53 | – |  | 0.861 | – | ||
 Yes | 8.5 (6.8–10.2) |  |  |  | 16.0 (12.7–19.3) |  |  |  |
 No | 9.1 (5.4–12.9) |  |  |  | 15.1 (13.0–17.3) |  |  |  |
Histology |  | 0.310 | – |  | 0.973 | – | ||
 Adenocarcinoma | 8.5 (6.5–10.5) |  |  |  | 16.0 (13.2–18.8) |  |  |  |
 Squamous | 11.7 (5.7–17.7) |  |  |  | 14.7 (7.8–21.5) |  |  |  |
KRAS mutant subtypes |  | 0.306 | 1.204(0.634–2.282) | 0.57 |  | 0.215 | 1.616(0.733–3.564) | 0.234 |
 G12C | 10.0 (8.3–11.8) |  |  |  | 15.4 (14.1–16.7) |  |  |  |
 non-G12C | 8.0 (5.7–10.3) |  |  |  | 19.7 (9.9–29.5) |  |  |  |
PD-L1 expression |  | 0.931 | 0.981(0.482–1.999) | 0.959 |  |  | 0.841(0.363–1.949) | 0.687 |
  < 1% | 9.2 (4.0–14.4) |  |  |  | 19.7 (10.9–28.5) |  |  |  |
  ≥ 1% | 10.5 (9.2–11.8) |  |  |  | 23.8 (14.3–33.3) |  |  |  |
PS score |  | 0.328 | – |  | 0.129 | – | ||
 0–1 | 9.0 (7.58–10.4) |  |  |  | 16.0 (12.8–19.2) |  |  |  |
  = 2 | 6.0 (5.5–6.5) |  |  |  | 13.0 (8.6–17.4) |  |  |  |
Stage |  | 0.788 | – |  | 0.582 | – | ||
 III | 10.8 (5.8–15.9) |  |  |  | 18.3 (11.4–25.2) |  |  |  |
 IVa | 9.1 (7.5–10.7) |  |  |  | 18.0 (13.3–22.7) |  |  |  |
 IVb | 9.8 (7.6–12.0) |  |  |  | 15.0 (12.0–18.0) |  |  |  |
Immunotherapy |  | < 0.001 | 0.350(0.156–0.781) | 0.010 |  | 0.013 | 0.522(0.183–0.1.490) | 0.174 |
 Yes | 11.7 (9.2–14.2) |  |  |  | 23.8 (11.3–36.3) |  |  |  |
 No | 7.0 (5.6–8.4) |  |  |  | 14.7 (12.3–17.1) |  |  |  |
Chemotherapy drugs |  | < 0.001 | 0.486 (0.255–0.928) | 0.029 |  | 0.112 | 0.573 (0.257–1.280) | 0.224 |
 containing pemetrexed | 10.1 (9.0–11.1) |  |  |  | 16.4 (9.9–22.9) |  |  |  |
 containing paclitaxel | 6.2 (4.7–7.7) |  |  |  | 14.1 (11.5–16.7) |  |  |  |
Antiangiogenic therapy |  | 0.031 | 0.355(0.159–0.790) | 0.011 |  | 0.004 | 0.333(0.120–0.926) | 0.035 |
 Yes | 10.0 (8.5–11.5) |  |  |  | 19.7 (11.8–27.6) |  |  |  |
 No | 6.5(4.7–8.4) |  |  |  | 13.7 (11.2–16.3) |  |  |  |